Paul Lorigan

The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit.

R. Stephens, F. Shepherd, M. Nankivell, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

J. Larkin, R. Plummer, P. Nathan, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Guidelines for the stratification of patients recruited to trials of therapy for low-risk gestational trophoblastic tumor.

P. Lorigan, R. Coleman, B. Hancock, 2000, Gynecologic oncology.

Radiotherapy for small-cell lung cancer-Where are we heading?

N. Bayman, B. Kularatne, H. Sheikh, 2009, Lung cancer.

Randomised phase III trial of docetaxel/carboplatin vs MIC/MVP chemotherapy in advanced non-small cell lung cancer (NSCLC) - final results of a British Thoracic Oncology Group (BTOG) trial.

R. Booton, K. O'Byrne, C. Faivre-Finn, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gestational choriocarcinoma of the ovary diagnosed by analysis of tumour DNA.

P. Lorigan, A. Grierson, J. Goepel, 1996, Cancer Letters.